Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay--a retrospective study

F Spyratos; P M Martin; K Hacène; C Andrieu; S Romain; J L Floiras; H Magdelénat

doi:10.1007/BF00666184

Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay--a retrospective study

Breast Cancer Res Treat. 1994 Jan;29(1):85-95. doi: 10.1007/BF00666184.

Authors

F Spyratos¹, P M Martin, K Hacène, C Andrieu, S Romain, J L Floiras, H Magdelénat

Affiliation

¹ Centre René Huguenin, Saint-Cloud, France.

PMID: 8018965
DOI: 10.1007/BF00666184

Abstract

In a retrospective study of 319 primary breast cancers, we show that an immunoenzymatic assay of a solubilized fraction of EGF receptors indicates a prognostic value for EGFR which is in contradiction with some (but not all) other studies. It appears that different methodological approaches of measuring EGFR are not equivalent in terms of prognostic power. We emphasize the need for rigorous multicentric standardization and quality control of assays, followed by multistep validation of parameters oriented towards clinical use.

Publication types

Clinical Trial
Comparative Study

MeSH terms

Aged
Biomarkers, Tumor / analysis*
Breast Neoplasms / chemistry*
Breast Neoplasms / drug therapy
Breast Neoplasms / pathology*
Breast Neoplasms / surgery
ErbB Receptors / analysis*
Female
Follow-Up Studies
Humans
Immunoenzyme Techniques
Lymphatic Metastasis
Middle Aged
Neoplasm Metastasis
Postmenopause
Premenopause
Prognosis
Receptors, Estrogen
Receptors, Progesterone
Retrospective Studies
Survival Analysis

Substances

Biomarkers, Tumor
Receptors, Estrogen
Receptors, Progesterone
ErbB Receptors